The CLIP1–LTK fusion is an oncogenic driver in non‐small‐cell lung

The CLIP1–LTK fusion is an oncogenic driver in non‐small‐cell lung cancer

The CLIP1–LTK fusion is an oncogenic driver in non‐small‐cell lung

Comparison of ALK and LTK structure and sequence. (A) Schematic of

Frontiers Recent progress in targeted therapy for non-small cell

Frontiers Cancer/Testis Antigens as Biomarker and Target for the Diagnosis, Prognosis, and Therapy of Lung Cancer

Tadashi Manabe MD, PhD on X: A whole new oncogenic driver in non-small-cell lung cancer found by the LC-SCRUM Asia. Very very impressive! / X

Frontiers Recent progress in targeted therapy for non-small cell

Frontiers Co-Occurring Potentially Actionable Oncogenic Drivers

Recombinant Anti-LTK antibody [EPR5175(2)] (ab129155)